Xin Sui1, Leilei Jiang1, Huajing Teng1, Lan Mi2, Bo Li1, Anhui Shi1, Rong Yu1, Dongming Li1, Xin Dong1, Dan Yang1, Huiming Yu1, Weihu Wang1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China. 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
Abstract
PURPOSE: To identify cytokines in plasma that may predict objective response and progression-free survival (PFS) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with chemoradiotherapy. MATERIALS AND METHODS: From April 2016 to May 2017, thirty-one patients with locally advanced inoperable/unresectable NSCLC were included, and treated with concurrent chemoradiotherapy (CCRT). No immune checkpoint inhibitors were administered after CCRT. Plasma from each patient was collected before radiotherapy, and 25 cytokines in the plasma were measured by Luminex or U-PLEX assays. Logistic regression and COX regression were performed to identify the predictive factors for objective response and PFS, respectively. Kaplan-Meier survival analysis was used to compare the PFS between the groups. RESULTS: High levels of IL-13 and TNF-α, and low levels of ICAM-1, IFN-γ, and soluble PD-L1 (sPD-L1) were significantly associated with objective response (P <0.05). High levels of IL-8, CCL5, and CXCL3 also showed a trend toward association with objective response (P <0.1). The combination of cytokines (IL-8 and ICAM-1, or TNF-α and sPD-L1) improved predictive accuracy. Univariate analysis identified IL-8 and ICAM-1 as potential markers to predict PFS. Multivariate analysis suggested that high level of IL-8 (P =0.010) and low level of ICAM-1 (P =0.011) correlated significantly with a longer PFS. CONCLUSION: IL-8 and ICAM-1 in plasma have the potential to predict objective response and PFS in patients with locally advanced NSCLC underwent chemoradiotherapy.
PURPOSE: To identify cytokines in plasma that may predict objective response and progression-free survival (PFS) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with chemoradiotherapy. MATERIALS AND METHODS: From April 2016 to May 2017, thirty-one patients with locally advanced inoperable/unresectable NSCLC were included, and treated with concurrent chemoradiotherapy (CCRT). No immune checkpoint inhibitors were administered after CCRT. Plasma from each patient was collected before radiotherapy, and 25 cytokines in the plasma were measured by Luminex or U-PLEX assays. Logistic regression and COX regression were performed to identify the predictive factors for objective response and PFS, respectively. Kaplan-Meier survival analysis was used to compare the PFS between the groups. RESULTS: High levels of IL-13 and TNF-α, and low levels of ICAM-1, IFN-γ, and soluble PD-L1 (sPD-L1) were significantly associated with objective response (P <0.05). High levels of IL-8, CCL5, and CXCL3 also showed a trend toward association with objective response (P <0.1). The combination of cytokines (IL-8 and ICAM-1, or TNF-α and sPD-L1) improved predictive accuracy. Univariate analysis identified IL-8 and ICAM-1 as potential markers to predict PFS. Multivariate analysis suggested that high level of IL-8 (P =0.010) and low level of ICAM-1 (P =0.011) correlated significantly with a longer PFS. CONCLUSION: IL-8 and ICAM-1 in plasma have the potential to predict objective response and PFS in patients with locally advanced NSCLC underwent chemoradiotherapy.
Authors: Elias A Kotteas; Ioannis Gkiozos; Sofia Tsagkouli; Antonios Bastas; Ioannis Ntanos; Muhammad W Saif; Konstantinos N Syrigos Journal: Med Oncol Date: 2013-07-25 Impact factor: 3.064
Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox Journal: J Natl Cancer Inst Date: 2011-09-08 Impact factor: 13.506
Authors: Christine Schröder; Isabell Witzel; Volkmar Müller; Sylke Krenkel; Ralph M Wirtz; Fritz Jänicke; Udo Schumacher; Karin Milde-Langosch Journal: J Cancer Res Clin Oncol Date: 2011-05-18 Impact factor: 4.553
Authors: L Boldrini; A Calcinai; E Samaritani; F Pistolesi; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Fontanini Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640